Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers.

@article{Zhi1994RetrospectivePA,
  title={Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers.},
  author={Jianguo Zhi and A. T. Melia and Roberto Guerciolini and Jae-yong Chung and J A Kinberg and Jonathan B Hauptman and Indravadan H. Patel},
  journal={Clinical pharmacology and therapeutics},
  year={1994},
  volume={56 1},
  pages={82-5}
}
Orlistat, an inhibitor of gastrointestinal lipases, limits the absorption of ingested fat and could become a potential treatment for obesity. This analysis was performed to elucidate the relationship between orlistat dose and intensity of inhibition of dietary fat absorption (assessed by measuring fecal fat excretion). In 11 phase I double-blind, placebo-controlled, parallel-group randomized studies, a total of 171 subjects received oral daily doses that ranged from 30 to 1200 mg orlistat or… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 63 extracted citations

White Paper AGA: POWER - Practice Guide on Obesity and Weight Management, Education, and Resources.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2017
View 1 Excerpt

Pharmacotherapy for Obesity.

Endocrinology and metabolism clinics of North America • 2016
View 1 Excerpt

Similar Papers

Loading similar papers…